[Source: Trading Markets] – ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen’s Homspera.
For more information: University of Rochester Medical Center Receives $15 Million in Government Funding to Research ImmuneRegen’s Homspera